Peeling Back The Layers: Exploring Pfizer Through Analyst Insights
Portfolio Pulse from Benzinga Insights
Pfizer (NYSE:PFE) has received mixed analyst ratings over the past three months, with 8 analysts offering varied opinions. The average 12-month price target is $41.25, up 12.49% from the previous $36.67. Analysts from firms including Cantor Fitzgerald, TD Cowen, Truist Securities, UBS, and Barclays have maintained or lowered their price targets, with ratings ranging from 'Overweight' to 'Neutral'. Pfizer's financials show a revenue decline of -41.55% as of September 30, 2023, a net margin of -18.0%, ROE of -2.43%, ROA of -1.09%, and a debt-to-equity ratio of 0.66.

January 31, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pfizer has a mixed outlook from analysts, with a recent average price target increase to $41.25. Financial indicators show a revenue decline and below-average profitability, which may concern investors.
The mixed analyst ratings and the increase in the average price target suggest a neutral short-term impact on PFE's stock price. The financial challenges indicated by the revenue decline and low profitability metrics may offset the potential positive impact of the increased price target.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100